Interactive Effects of Serum Leptin Levels and Physical Comorbidity on the Pharmacotherapeutic Response of Depressive Disorders

키워드

참고문헌 (61)

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 392, pp.1789~1858 (2018)
2. Chiara Fabbri, "How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach", Clinical Psychopharmacology and Neuroscience, 18(4), pp.484~492 (2020), 대한정신약물학회[DOI]
3. Cipriani A, "Comparative efficacy and acceptability of 21antidepressant drugs for the acute treatment of adults with major depressive disorder : a systematic review and network meta-analysis", Lancet, 391, pp.1357~1366 (2018)
4. Trivedi MH, "Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D : implications for clinical practice", Am J Psychiatry, 163, pp.28~40 (2006)
5. Sanches M, "New agents and perspectives in the pharmacological treatment of major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 106, pp.110157~ (2021)
6. Otero M, "Leptin : a metabolic hormone that functions like a proinflammatory adipokine", Drug News Perspect, 19, pp.21~26 (2006)
7. Tartaglia LA, "Identification and expression cloning of a leptin receptor, OB-R", Cell, 83, pp.1263~1271 (1995)
8. Feinkohl I, "Plasma leptin, but not adiponectin, is associated with cognitive impairment in older adults", Psychoneuroendocrinology, 120, pp.104783~ (2020)
9. Lu XY, "Leptin : a potential novel antidepressant", Proc Natl Acad Sci U S A, 103, pp.1593~1598 (2006)
10. Chuang JC, "A beta3-adrenergic-leptin-melanocortin circuit regulates behavioral and metabolic changes induced by chronic stress", Biol Psychiatry, 67, pp.1075~1082 (2010)
11. Yamada N, "Impaired CNS leptin action is implicated in depression associated with obesity", Endocrinology, 152, pp.2634~2643 (2011)
12. Guo M, "Selective deletion of leptin receptors in adult hippocampus induces depression-related behaviours", Int J Neuropsychopharmacol, 16, pp.857~867 (2013)
13. Guo M, "Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates", Transl Psychiatry, 4, pp.e486~ (2014)
14. Garza JC, "Leptin restores adult hippocampal neurogenesis in a chronic unpredictable stress model of depression and reverses glucocorticoid-induced inhibition of GSK-3β", β-catenin signaling, 2012, pp.17, 790~808
15. Arvaniti K, "Effects of leptin and corticosterone on the expression of corticotropin-releasing hormone, agouti-related protein, and proopiomelanocortin in the brain of ob", ob mouse, 2001, pp.73, 227~236
16. Komori T, "Induction of brainderived neurotrophic factor by leptin in the ventromedial hypothalamus", Neuroscience, 139, pp.1107~1115 (2006)
17. Charnay Y, "Intracerebroventricular infusion of leptin decreases serotonin transporter binding sites in the frontal cortex of the rat", Neurosci Lett, 283, pp.89~92 (2000)
18. Zou X, "Role of leptin in mood disorder and neurodegenerative disease", Front Neurosci, 13, pp.378~ (2019)
19. Kraus T, "Low leptin levels but normal body mass indices in patients with depression or schizophrenia", Neuroendocrinology, 73, pp.243~247 (2001)
20. Yang K, "Levels of serum interleukin(IL)-6, IL-1beta, tumour necrosis factoralpha and leptin and their correlation in depression", Aust N Z J Psychiatry, 41, pp.266~273 (2007)
21. Jow GM, "Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia", J Affect Disord, 90, pp.21~27 (2006)
22. Gecici O, "High serum leptin levels in depressive disorders with atypical features", Psychiatry Clin Neurosci, 59, pp.736~738 (2005)
23. Milaneschi Y, "Leptin dysregulation is specifically associated with major depression with atypical features : evidence for a mechanism connecting obesity and depression", Biol Psychiatry, 81, pp.807~814 (2017)
24. Morris AA, "The association between depression and leptin is mediated by adiposity", Psychosom Med, 74, pp.483~488 (2012)
25. Kloiber S, "Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels", Eur Neuropsychopharmacol, 23, pp.653~662 (2013)
26. Lopresti AL, "Curcumin and major depression : a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change", Eur Neuropsychopharmacol, 25, pp.38~50 (2015)
27. Shelton RC, "Association of obesity and inflammatory marker levels on treatment outcome : results from a doubleblind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs", J Clin Psychiatry, 76, pp.1635~1641 (2015)
28. Machado-Vieira R, "The role of adipokines in the rapid antidepressant effects of ketamine", Mol Psychiatry, 22, pp.127~133 (2017)
29. Münzberg H, "Molecular and anatomical determinants of central leptin resistance", Nat Neurosci, 8, pp.566~570 (2005)
30. Wells KB, "Psychiatric disorder in a sample of the general population with and without chronic medical conditions", Am J Psychiatry, 145, pp.976~981 (1988)
31. Keitner GI, "12-month outcome of patients with major depression and comorbid psychiatric or medical illness(compound depression)", Am J Psychiatry, 148, pp.345~350 (1991)
32. Koike AK, "Improving the care for depression in patients with comorbid medical illness", Am J Psychiatry, 159, pp.1738~1745 (2002)
33. Oslin DW, "Association between medical comorbidity and treatment outcomes in late-life depression", J Am Geriatr Soc, 50, pp.823~828 (2002)
34. Kim JM, "Physical comorbidity and 12-week treatment outcomes in Korean patients with depressive disorders : the CRESCEND study", J Psychosom Res, 71, pp.311~318 (2011)
35. Ciprandi G, "Serum leptin levels depend on allergen exposure in patients with seasonal allergic rhinitis", Immunol Invest, 38, pp.681~689 (2009)
36. Seven A, "Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis", Rheumatol Int, 29, pp.743~747 (2009)
37. Esteghamati A, "Association of serum leptin levels with homeostasis model assessment-estimated insulin resistance and metabolic syndrome : the key role of central obesity", Metab Syndr Relat Disord, 7, pp.447~452 (2009)
38. de Boer TN, "Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage", Osteoarthritis Cartilage, 20, pp.846~853 (2012)
39. Trejo-Vazquez F, "Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease : a case-control study", Exp Ther Med, 15, pp.3336~3344 (2018)
40. Gu L, "Association of serum leptin with breast cancer: a meta-analysis", Medicine(Baltimore), 98, pp.e14094~ (2019)
41. Hee-Ju Kang, "The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology", PSYCHIATRY INVESTIGATION, 15(5), pp.538~545 (2018), 대한신경정신의학회
42. Sheehan DV, "The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10", J Clin Psychiatry, 59(Suppl 20), pp.22~33 (1998)
43. Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
44. Hickey MS, "Gender differences in serum leptin levels in humans", Biochem Mol Med, 59, pp.1~6 (1996)
45. Hellström L, "Mechanisms behind gender differences in circulating leptin levels", J Intern Med, 247, pp.457~462 (2000)
46. WHO Expert Consultation, "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies", Lancet, 363, pp.157~163 (2004)
47. Zigmond AS, "The hospital anxiety and depression scale", Acta Psychiatr Scand, 67, pp.361~370 (1983)
48. Rabin R, "EQ-5D : a measure of health status from the EuroQol Group", Ann Med, 33, pp.337~343 (2001)
49. Kim JM, "Short and long-term treatment outcomes of stepwise psychopharmacotherapy based on early clinical decision in patients with depressive disorders", J Affect Disord, 274, pp.315~325 (2020)
50. Anderson IM, "Evidence-based guidelines for treating depressive disorders with antidepressants : a revision of the 2000British Association for Psychopharmacology guidelines", J Psychopharmacol, 22, pp.343~396 (2008)
51. Bauer M, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of unipolar depressive disorders, part 1 : update 2013 on the acute and continuation treatment of unipolar depressive disorders", World J Biol Psychiatry, 14, pp.334~385 (2013)
52. Malhi GS, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 49, pp.1087~1206 (2015)
53. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
54. Kim JM, "Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders : the CRESCEND study", J Affect Disord, 129, pp.183~190 (2011)
55. Stassen HH, "Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients", J Clin Psychiatry, 68, pp.1195~1205 (2007)
56. Szegedi A, "Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression", J Clin Psychiatry, 64, pp.413~420 (2003)
57. Swift JK, "The impact of client treatment preferences on outcome : a meta-analysis", J Clin Psychol, 65, pp.368~381 (2009)
58. Gruzdeva O, "Leptin resistance : underlying mechanisms and diagnosis", Diabetes Metab Syndr Obes, 12, pp.191~198 (2019)
59. Maffei M, "Leptin levels in human and rodent : measurement of plasma leptin and ob RNA in obese and weight-reduced subjects", Nat Med, 1, pp.1155~1161 (1995)
60. Havel PJ, "Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women : effects of dietary fat content and sustained weight loss", J Clin Endocrinol Metab, 81, pp.4406~4413 (1996)
61. Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)

관련 논문AI추천